Previous 10 | Next 10 |
Cash and restricted cash of $50.3 million as of December 31, 2021 Visionary-MS Phase 2 Trial unblinded results expected 2H 2022 Healey ALS Platform Trial top-line data expected 2H 2022 COVID-19 Phase 2 Trial top-line results expected mid-year 2022...
SALT LAKE CITY, March 03, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative d...
VISIONARY-MS Phase 2 blinded interim data suggest clinically relevant improvements in the modified MS Functional Composite for the study population through 48 weeks of treatment REPAIR-MS Phase 2 clinical trial demonstrated improved brain energetic metabolism following CNM-A...
SALT LAKE CITY, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative di...
Healey ALS Platform Trial fully enrolled; top-line data expected 2H 2022 Significant survival benefit from RESCUE-ALS open label extension (OLE) Phase 2 trial to be presented at upcoming Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Nashvil...
Clene (NASDAQ:CLNN) appointed seasoned healthcare executive and public-company biopharma CFO, Morgan Brown as CFO, effective Feb.1, 2022, succeeding CFO Ted Jeong. Mr. Brown's extensive experience in executive finance roles includes four publicly traded life science compan...
SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerativ...
Topline data is expected in 1H 2022 Trial is evaluating acutely symptomatic, non-hospitalized COVID-19 patients in Brazil CNM-ZnAg is a proprietary zinc-silver ionic solution that has demonstrated both antiviral and antibacterial activity . SALT LAKE CITY, Ja...
Powerful combination of key patents comes as the Company looks ahead to topline results from a Phase 3 registration study in ALS in second half of 2022 SALT LAKE CITY, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene...
Clene (CLNN +10.2%)and its wholly owned subsidiary Clene Nanomedicine announced a $1M grant award from the Maryland Department of Housing and Community Development (DHCD) to further support the redevelopment of the Clene manufacturing facility in Elkton, MD. Clene Nanomedicine is a ...
News, Short Squeeze, Breakout and More Instantly...
Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a...
Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease . This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubli...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...